Biotech Firm CinCor Pharma Kicks Off Nasdaq IPO Roadshow
Clinical-stage biopharmaceutical company CinCor Pharma, Inc. is setting its sights on trading at the Nasdaq Global Market. The firm announced
Read more
Biotech
MindMed Concludes Phase 1 Clinical Trial Of Psychedelic Derivative Drug For Opioid Use Disorder
Mind Medicine Inc. (NEO: MMED), more commonly known as MindMed, has recently concluded the phase 1 clinical trial for its
Read more
ALS Biotech Firm Amylyx Pharmaceuticals Launches Nasdaq IPO
Clinical-stage biopharmaceutical company Amylyx Pharmaceuticals is looking to go public on the Nasdaq Global Select Market. The firm announced today
Read more
Revive Therapeutics Adds Turkish Subjects To Bucillamine Phase 3 Clinical Trial For COVID-19
Revive Therapeutics (CSE: RVV) announced on Wednesday that it has expanded its phase 3 clinical trial for oral drug bucillamine as
Read more
Samsung In Talks To Acquire Biotech Firm Biogen In A US$42 Billion Deal
The Samsung Group is reportedly in negotiations to acquire biotech firm Biogen (Nasdaq: BIIB). The US firm approached the South Korean
Read more
Covalon Tech Sees CFO Quit, No Replacement Named
What better time to announce the departure of your chief financial officer, than the day before Christmas when the Canadian
Read more
Biotech Firm Senti Bio To Be Taken Public In A $601 Million SPAC Merger
Senti Biosciences, Inc., also known as Senti Bio, has announced a business combination agreement with special purpose acquisition company Dynamics
Read more
Pfizer To Acquire Clinical-Stage Biotech Firm Arena Therapeutics For US$6.7 Billion
Pfizer Inc. (NYSE: PFE) announced on Monday the definitive agreement to acquire clinical stage biopharmaceutical firm Arena Therapeutics (Nasdaq: ARNA).
Read more
Compass Pathways President Steps Down To An Advisory Role
Compass Pathways (Nasdaq: CMPS) announced this morning major changes to its executive team. One of its co-founders, President and Chief Business
Read more
Biopharmaceutical Firm Cingulate Prices US$25 Million IPO
Clinical-stage biopharmaceutical company Cingulate Inc. (Nasdaq: CING) began trading on the Nasdaq Capital Market today. The firm’s initial public offering
Read more